HLA-B*40 Allele Plays a Role in the Development of Acute Leukemia in Mexican Population: A Case-Control Study

Table 4

Subgroups based on age of patients with ALL and AML, compared with umbilical cord blood samples as a control group.

Allele	ALL patients		Controls, 𝑁=731		𝑃	OR	95% CI
	𝑛	g. f.	𝑛	g. f.
𝑁=186, ≤18 years old
B*39	47	0.1263	254	0.1737	0.01	0.63	0.43–0.93
B*40	56	0.1505	144	0.0984	0.002	1.76	1.20–2.56
𝑁=27, >18 years old
B*39	5	0.0925	254	0.1737	NS
B*40	4	0.0740	144	0.0984	NS
Allele	AML patients		Controls, 𝑁=731		𝑃	OR	95% CI
	𝑛	g. f.	𝑛	g. f.
𝑁=52, ≤18 years old
B*15	1	0.0096	135	0.0923	0.002	0.09	0.0–0.59
B*27	5	0.0480	19	0.0129	0.004	3.99	1.24–11.9
B*40	5	0.0480	144	0.0984	NS
𝑁=28, >18–59 years old
B*15	0	—	135	0.0923	NS
B*27	3	0.0535	19	0.0129	0.01	4.5	1.0–17.5
B*40	3	0.0535	144	0.0984	NS
𝑁=5, >59 years old
B*15	1	0.1000	135	0.0923	NS
B*27	1	0.1000	19	0.0129	0.01	9.37	0.18–99.9
B*40	0	—	144	0.0984	NS

ALL: acute lymphoid leukemia; AML: acute myeloid leukemia; g. f.: gene frequency; OR: odds ratio; CI: confidence interval; NS: not significant.